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Leukotriene B 4 is a highly potent leukocyte chemotac-
tic compound . It h as been identified in chamber fluid 
and scale from psoriatic skin lesions, in which epidermal 
neutrophil infiltration is reported to be one of the ear-
liest pathologic events. The ability of leukotriene B4 to 
reproduce the inflammatory events of psoriasis, by top-
ical application to the skin of normal human volunteers, 
was thus studied . Persistent visible inflammatory reac-
tions were elicited by application of amounts of leuko-
tr iene B 4 as low as 5 ng, and the maximum diameters of 
the reactions were dose-related up to at least 500 ng. 
The visible reactions appeared 12-24 h after initial 
application of leukotriene B4, and persisted for several 
days, leaving brownish pigmentation and scaling at 7 
days. His tologic examination showed intraepidermal 
neutrophil microabscesses at 24 h, but these had re-
solved b y 48 h. A mixed, perivascular neutrophil and 
mononuclear cell infiltrate was seen in the dermis at 24 
h , becoming predominantly mononuclear after 24 h. 
Nonspecific chemical irritant contact dermatitis was 
excluded b y the absence of reactions to high doses of two 
chemically similar metabolites of arachidonic acid 
which lack significant in vitro chemokinetic activity. 
These experiments provide further evidence for the role 
of leukotrie ne B4 in the pathogenesis of psoriasis, and 
may lead to the development of an experimental model 
of the inflammatory events in psoriasis, and of a simple 
in vivo test of neutrophil function. 
The a rac hidonate li poxygenase metabolite, leukotriene B4 
(58, l2R-di hydroxy-6, 14-cis-8, 10-trans-e icosatetraenoic acid) is 
one of th e most. potent neutrophil chemotactic compounds 
known \1 ,2 \. It. has recently bee n reported to be present in 
surface sca le [3,4] a nd in cha mber fluid [5] from the lesional 
s kin of patients with pso ri as is. 
Studi es in expe rimenta l animals [6] and in human volun teers 
[7,8 ] have s hown that leukotriene B4 is capable of inducing a 
dermal polymorphonuclear leuk ocyte infiltrate on intraderma l 
injection . These findin gs have led to t he suggestion t hat the 
re lease of leu kotri ene B, in the epidermis may play a role in 
the pathoge nes is o f pso ri asis [5], in which epidermal neutrophil 
infil t rat ion is reported to be one of t he earliest events in the 
evolut ion of t he skin lesion [9]. 
T he lipid nature o f leukotri ene B,, suggested t hat it might be 
absorbed percuta neo us ly after topica l a pplication, a nd that thi s 
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might lead to high epidermal concentrations. Any con sequen t 
neutrophil infiltration might be directed toward the epidermis, 
mimicking t he inflammatory events in psoriasis more closely 
than would be possible with intradermal injection ofleukotriene 
B4 • A study of the effects of topical application of leukotriene 
B4 a nd of appropriate control substances was therefore carried 
out. 
MATERIALS AND METHODS 
Chemically synthesized leukot riene B4 and 20-carboxy-leukotriene 
B, were kindly supplied by Dr. J . Rokach, Merck Frosst, Montreal. 
8,15-Dihydroxy-eicosatetraenoic acid (8,15-diHETE) was synthesized 
from arachidonic acid by using soybean lipoxygenase and sodium 
borohydride reduction, and was purified by Lipidex 5000 gel partition 
chromatography, reversed phase high-performance liquid chromatog-
raphy (HPLC) , and straight phase HPLC [10] . Its identity was con-
firmed by gas ch romatography-mass spectrometry. All compounds were 
quantified by UV absorbance spectrophotometry and were stored in 
ethano lic solu tion at -20"C. The in vi t ro leukocyte-stimulating prop-
ert ies of these compounds were dete rmined in an agarose microdroplet 
chemokinesis assay. The cells used in this assay were prepared from 
fresh human venous blood by dextran sedimentation and centrifuga-
tion, and consisted of 70- 80% neutrophils [3,11). 
Volunteers for topical application experiments were healthy mem-
bers of the Institute and hospital staff, aged 21- 49 years, and included 
8 males and 2 females. Nine were of European descent and one was 
Japanese. None had taken any medication for at least a week prior to 
the experiments. All gave informed consent to the experiments, and 
prior Ethical Committee approval was obtained. The in vivo experi-
ments in these volunteers were carried out on the flexor aspect of the 
forearm . Open-ended, silanized glass cylinders (internal diameter 5.5 
mm) were held vertically against the skin surface. The test compound 
in ethanolic solu t ion (0.5- 20 11!) was pipetted onto the skin surface 
within the confines of the glass cylinder, by using a microsyringe. The 
ethanol was evaporated under a stream of nitrogen, and the glass 
cylinder was removed, leaving a localized, dried deposit on the skin 
surface. The deposit was then occluded by application of a Finn 
Chamber held in place with Scanpor (Epitest Ltd., Helsinki) , as used 
in routine patchtesting procedures. The Finn Chamber was removed 
after 6 h. 
Dose- response studies were carried out in 7 voluntee rs. Leukot riene 
B., was applied as desc ribed to the forearms of each subject in the 
following quantities: 0.5, 1, 5, 10, 50, 100, and 500 ng. All 7 subjects 
also received app lications of 20-ca rboxy- leukotriene B, (1 11g) , 8,15-
diHETE (1 11g), and 20 11! ethanol alone. 
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Histologic studies were done in 5 subjects (including 2 subjects who 
had undergo ne dose-response studies) at various time intervals after 
100 ng leukotriene B 4 had been applied. Punch biopsies (3-4 mm 
diameter, obtained after infil tration of the skin with 2% lignocaine) 
were subjected to paraf"!in section by standard methods. Sections were 
sta ined with hematoxylin and eosin and were examined by light mi-
croscopy. A total of 15 biopsies was obtained from reaction sites (5 
biopsies at 24 h, 2 biopsies at 6, 12, 48, and 96 h, and 1 biopsy at 72 h 
and 7 days), as well as 3 biopsies from normal skin. 
RESULTS 
In the agarose microdroplet chemokines is assay leukotriene 
B4 was shown to be a highly potent stimulato r of leukocyte 
mobility, as is well kn ow n [1 ,2 ]. An ED50 value of 2.5 X 10- 10 
M was obta ined, whe reas 20-carboxy-leukotriene B4 and 8,15-
diHETE showed negli gible activity (Fig l). 
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FIG 1. Chemok inetic act ivity of Jeukotriene 8 4 (e), 20-carboxy-
le ukot riene B., (..t.), and 8,15-diHETE (•). Chemokinetic movement is 
expressed as tbe distance moved by leukocytes from the agarose droplet, 
in t he described assay. Each poin t represents the mean of 9 assays. 
The SE in each case was less t han 15% of the mean. 
In the in vivo dose-response studies, no visible changes were 
seen at the sites of application of 20-carboxy-leukotriene B.~, 
8, 15-diHETE, the ethanol blank, or 0.5 ng and 1 ng leukotriene 
R~o in any subject. Larger amounts of L TB4 induced reactions 
t hat became visible 12-24 h a fter ini t ia l application . At 5 ng 
leukotriene B.~, 6 of 7 subjects developed well-defined erythema 
a nd 4 of these additionally had swelling. At 10 ng leukotriene 
B 4 or greate r, a ll subjects developed well-defined erythema and 
swelling. In one subject a t ransient vesicle of 3-mm diameter, 
on an erythematous base, was seen at t he 10-ng site at 4 days. 
In t he same subject transient pustules surmounted the ery-
t hema and swelling at 100- and 500- ng sites at 48 h, changing 
to clear, flaccid vesicles at 72 h. By 96 h the vesicles had 
subsided, leaving only erythema and swelling. In one other 
subject clear vesicles surmounted erythema and swelling at the 
500-ng site at 24 h, but only erythema and swelling were visible 
at 48 h. The diameters of t he reactions were maximal at 20- 48 
h. The mean maximum diameters of the reactions were dose-
related and a re given in Table I. After this t ime the erythema 
and swelling gradually diminished, so that by 7 days a ll reaction 
sites showed macula r brownish pigmentation with variable 
degrees of superficial scaling. There was no significant itc h, 
pain , or tenderness at any stage of these reactions. 
Histologic examination of both biopsies taken 6 h after 
application of 100 ng leukotriene B. showed no significant 
pathology when compared wit h normal skin. In both biopsies 
at 12 h, vessels in the papillary dermis were surrounded by 
edema and extravasated red blood cells. In addi t ion, a mixture 
of mononuclea r cells and polymorphonuclear leukocytes was 
seen within vascula r lumina and walls, and in the immediate 
perivascula r space. Numerous neutrophil polymorphonuclea r 
leukocytes were located between vessels and t he overlying 
epidermis . The lower layers of the epidermis were infil trated 
by a population of neutrophils arra1~ged singly or in groups and 
TABLE I. Mean maximum diameters of leuhotrien.e B., reactions 
Leukot.ri ene 8, Mean diamete r so· Number of 
dose (ng) (mm) (mm ) subjects 
5 3.4 0.4 6b 
10 3.9 0.7 7 
50 5.7 1.0 7 
100 6.4 1.3 7 
500 8.9 0.7 7 
Dia meters were measured to t he nearest 0.5 mm , but means a nd SD 
are given to t he nearest 0.1 mm. 
• Standard dev iation of the mea n. 
bO ne subject did not respond to the 5-ng dose . 
F IG 2. Histologic appearance of the 24- h Jeukotriene 8 4 reaction. 
The upper epidermis is occupied by several vacuoles conta ining nu-
merous intact neutrophils (H & E stain , bar= 50 pm ). 
contai ned within rounded spaces or vacuoles . At 24 h the 
histopathologic changes were pa rt icul a rly strikin g, wi th nu -
merous vacuoles, filled with neutrophils, occupying the upper 
part of t he prickle cell layer (Fig 2) . T he vacuoles were of 
different sizes and some had coa lesced to form la rger subcorneal 
microabscesses. The dermal changes at 24 h were simila r to 
those seen at 12 h. B iops ies ta ken between 48 h and 7 days 
showed epidermal changes consistent wit h a reso lving in flam-
matory reaction. In both biopsies at 48 h, vacuoles had dis-
appeared from the prickle cell layer but t heir contents could 
sti ll be discerned within t he stratum corneum . There was Joss 
of the granula r cell layer and a th in layer of para keratosis 
separating t he prickle cell layer from the ove rlying stratu m 
corneum. As the lesions aged the layer of parakeratos is moved 
outward t hrough the stratum corneum and was replaced by a 
normal granular cell layer in the two biopsies at 96 h. Wi thin 
t he dermis the two 48-h biopsies showed a predom inantly 
mononuclear cell in fil trate a round dermal vessels. Only a few 
in tact polymorphonuclear leukocytes were seen eit her wi thin 
the perivascular infi ltrate or in t he surrounding dermis, t hough 
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nuc lea r dust was a prominent feature. A sign ificant perivascular 
mononuclear infil trate remained vis ible in all biopsies up to 7 
days. 
DISCUSSJON 
These resu lts s how that leukotriene 8.1, in doses as low as 5 
ng, elici ts a vis ible in!1ammatory reaction when applied topi-
ca lly to no rmal skin. The spec ifi city of this e ffect is demon -
st rllt.ed hy t.he absence of visible reactions to 20-ca rboxy- leu-
kotri ene B, (1 p.g) and 8,15-diHETE (1 p..g), both of which have 
negligible leuk ocyte-stimulating properties (Fig 1) but are 
chem ica ll y simila r to leukotriene R, . 20-Carboxy- leukotriene 
B., i a metabo li te of leukot riene B.., form ed in neutrophils 
112]. 8, 15- DiHETE, an isomer of leukotriene B,, is a compound 
of unknown biologic s ignificance, form ed from a rachidonic acid 
in eosinophils [13). This ev idence, taken together with t he 
hi stopathologic findings , indicates that the effect of leukotriene 
B, is not due to a nonspecific chem ica l irritant reaction. 
The hi stopathologic changes described demonstrate a unique 
sequence of events which show that accumulation of a chemo-
tactic agent in t he epiderm is is capab le of el icit ing intraepider-
ma l neut rophil mic roabscesses. This reaction cou ld represent a 
pha rmacologic and histopathologic model of t he inflammatory 
eve nts in pso riasis. However, there are severa l histopathologic 
features that distingui sh the leukotriene B., reaction at 24 h 
from an establi shed psoriatic lesion. The granu lar cell layer is 
intact and the overly ing stratum corneum is normal in the 24-
h react ion, a lthough t he gra nular cell layer is absen t in 48- and 
72- h biopsies. ln addition, at 24 h t he cells within the epidermis 
a re a lmost exc lusively neutrophils, whereas in psoriasis signif-
icant epidermal mononuclear cell infiltrates are a lso seen [14). 
Finally, a lt hough spongiosis is not a prominent feature of 
chronic plaque psoriasis , it is invariably seen in pustular pso-
riasis, and the ep idermi s adjacent to microabscesses showed no 
ev idence of spongiosis in any of t he leukotriene B, reactions 
studied. However, the reactions studied represent an acute, 
relatively short-li ved process, and features more closely resem -
bling psorias is might be obta ined with t he chronic application 
o f lower doses of leukotriene B,. These experiments are in 
progress. It is a lso possible t hat t he observed reactions to 
leukotri ene R, could be reproduced by other chemotactic com-
pounds which are applied topically and absorbed percuta-
neously. 
Although t hese results provide further evidence for the rol e 
of Jeukotriene B, in the pathogenes is o f psorias is, and a lthough 
it has been claimed that epidermal neutrophil infiltration is 
one of the ea rliest events in t he evo lution of the psoriatic lesion 
191, it is not yet known whether t he release of leukotriene B, 
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in psoriatic Jesional skin is a primary or seconda ry event. 
Ultimate dete rmination of its ro le in psoriasis must awa it the 
avai labi li ty of specific inhibito rs of leukotriene R, synthesis, or 
specific receptor antago nists. 
The top ical Jeukotriene 8 4 reaction also appears to be a 
s imple, reproducible model o f in vivo neutrophil chemotaxis. I t 
is our intention to pursue these studies in patients with defec-
tive neutrophil function , a nd to determine the effects of phar-
macologic and t herapeutic agents on t he leukotriene B 4 reac -
tio n. 
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